ProShare Advisors
IKT icon

ProShare Advisors’s Inhibikase Therapeutics IKT Stock Holding History

ProShare Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.1K Buy
15,537
+4,491
+41% +$7.97K ﹤0.01% 1831
2025
Q4 		$22.6K Buy
11,046
+705
+7% +$1.12K ﹤0.01% 2017
2025
Q3 		$16.8K Sell
10,341
-2,060
-17% -$3.57K ﹤0.01% 1997
2025
Q2 		$24.2K Buy
+12,401
New +$24.3K ﹤0.01% 2058

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ProShare Advisors's IKT Position: Q1 2026 in Review

ProShare Advisors increased its Inhibikase Therapeutics (IKT) stake by 41% in Q1 2026, buying an estimated $7.97K and bringing the position to 15,537 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1831.

ProShare Advisors first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • ProShare Advisors held 15,537 shares of Inhibikase Therapeutics worth $26.1K as of Q1 2026.
  • ProShare Advisors bought 4,491 Inhibikase Therapeutics shares in Q1 2026, an estimated $7.97K.
  • Inhibikase Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1831 holding.
  • ProShare Advisors first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.